How big is the Injectable Anti-diabetic Drugs Market?

The Injectable Anti-diabetic Drugs Market size is expected to reach USD 38.79 billion in 2024 and grow at a CAGR of greater than 3% to reach USD 45.10 billion by 2029. Read More

What is the current Injectable Anti-diabetic Drugs Market size?

In 2024, the Injectable Anti-diabetic Drugs Market size is expected to reach USD 38.79 billion. Read More

Who are the key players in Injectable Anti-diabetic Drugs Market?

Novo Nordisk, Lilly, Julphar, Biocon and Sanofi are the major companies operating in the Injectable Anti-diabetic Drugs Market. Read More

Which is the fastest growing region in Injectable Anti-diabetic Drugs Market?

North America is estimated to grow at the highest CAGR over the forecast period (2023-2029). Read More

Which region has the biggest share in Injectable Anti-diabetic Drugs Market?

In 2023, the North America accounts for the largest market share in Injectable Anti-diabetic Drugs Market. Read More

What years does this Injectable Anti-diabetic Drugs Market cover, and what was the market size in 2023?

In 2023, the Injectable Anti-diabetic Drugs Market size was estimated at USD 37.63 billion. The report covers the Injectable Anti-diabetic Drugs Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Injectable Anti-diabetic Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Injectable Anti-diabetic Drugs Market Share

Statistics for the 2023 & 2024 Injectable Anti-diabetic Drugs market share, created by Mordor Intelligence™ Industry Reports. Injectable Anti-diabetic Drugs share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Injectable Anti-diabetic Drugs Industry

The injectable anti-diabetic drugs market is consolidated, with major manufacturers, namely Eli Lilly, Novo Nordisk, and Sanofi, among others, holding a presence in all regions. Mergers and acquisitions that have happened between the players in the recent past helped the companies strengthen their market presence. For instance, Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).